Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy

CNS Drugs

Volumn 22, Issue 1, 2008, Pages 27-47

  Johannessen Landmark, Cecilie ^a  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

Antiepileptic drugs, general; Anxiety; Bipolar disorders; Essential tremor; Migraine; Neuropathic pain; Schizophrenia

Indexed keywords

10 ACETOXY 10,11 DIHYDRO 5H DIBENZ[B,F]AZEPINE 5 CARBOXAMIDE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BRIVARACETAM; CALCIUM CHANNEL; CARBAMAZEPINE; DIAZEPAM; DIZOCILPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; ION CHANNEL; ISOVALERAMIDE; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; SELETRACETAM; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; VOLTAGE GATED SODIUM CHANNEL; XP 13512; ZONISAMIDE;

ALCOHOL ABUSE; ANXIETY; BIPOLAR DISORDER; CANCER; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG ABUSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; EPILEPSY; ESSENTIAL TREMOR; GABAERGIC SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; NERVE EXCITABILITY; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPSE;

EID: 36949037520     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822010-00003     Document Type: Review

References (153)

1. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-75
2. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10: 685-92
3. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-64
4. Zaremba PD, Bialek M, Blasczcyk B, et al. Non-epilepsy uses of antiepilepsy drugs. Pharmacol Rep 2006; 58: 1-12
5. Golden AS, Haut S, Moshé SL. Nonepileptic uses of antiepileptic drugs in children and adolescents. Ped Neurol 2006; 34: 421-32
6. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007; 4: 75-83
7. Goodnick PJ. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 2006; 7: 401-10
8. Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 2006; 68: 22-8
9. Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005; 46 Suppl. 4: 31-7
10. Stefan H, Lopes da Silva FH, Löscher W, et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand 2006; 113: 139-55
11. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 2005; 63: 141-9
12. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-94
13. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (Eilat VII). Epilepsy Res 2004; 61: 1-48
14. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat conference (Eilat VIII). Epilepsy Res 2007; 73: 1-52
15. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64: 21-7
16. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37: 133-46
17. Johannessen CU, Petersen D, Fonnum F, et al. The acute effect of valproate on cerebral energy metabolism in mice. Epilepsy Res 2001; 47: 247-56
18. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-94
19. Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in gamma-aminobutyric acid A receptor alpha 1 subunit knockout mice. J Clin Invest 2005; 115: 584-6
20. Jankovic J, Noebels JL. Genetic mouse models of essential tremor: are they essential? J Clin Invest 2005; 115: 774-9
21. Pathwa R, Lyons KE. Essential tremor: differential diagnosis and current therapy. Am J Med 2003; 115: 134-42
22. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996; 36: 579-85
23. Yee BK, Keist R, von Boehmer L, et al. Schizophrenia-related sensorimotor deficit links alpha-3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci 2005; 22: 102: 17154-9
24. Volk DW, Austin MC, Perri JN, et al. Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57: 237-45
25. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 363-82
26. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258-66
27. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46: 1097-104
28. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-13
29. Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Mol Brain Res 2003; 116: 1-6
30. McQuay H, Caroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-52
31. Coderre TJ, Kumar N, Lefebyre CD, et al. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94: 1131-9
32. Yang RH, Xing JL, Duan JH, et al. Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG. Pain 2005; 116: 187-93
33. Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci 2006; 100: 471-86
34. Tanabe M, Sakaue A, Takasu K, et al. Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Nauyn Schmiedebergs Arch Pharmacol 2005; 372: 107-14
35. Imamura Y, Bennett GJ. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. J Pharmacol Exp Ther 1995; 275: 177-82
36. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylases is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41
37. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-60
38. Bachmann RF, Schloesser RJ, Gould TD, et al. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005; 32: 173-202
39. Shaltiel G, Shamir A, Shapiro J, et al. Valproate decreases inositol synthesis. Biol Psychiatry 2004; 56: 868-74
40. Evins AE, Demopulos C, Yovel I, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006; 8: 168-74
41. Ju S, Greenberg ML. Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Mol Microbiol 2003; 49: 1595-603
42. Williams RSB, Cheng L, Mudge AW, et al. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-6
43. Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 2003; 6: 181-9
44. Lieb K, Treffurth Y, Hamke M, et al. Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J Neurochem 2003; 86: 69-76
45. Chetcuti A, Adams LJ, Mitchell PB, et al. Altered gene expression in mice treated with the mood stabilizer sodium valproate. Int J Neuropsychopharmacol 2005; 28: 1-10
46. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119-30
47. Sechi GP, Traccis S, Durelli L, et al. Carbamazepine versus diphenylhydantoin in the treatment of myotonia. Eur Neurol 1983; 22: 113-8
48. Rodrigues JP, Edwards DJ, Walters SE, et al. Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Mov Disord 2005; 20: 865-70
49. Keck PE, Strawn JR, McElroy LR. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2005; 67: 8-15
50. Zesiewicz TA, Elbe R, Louis ED, et al. Practice parameter: therapies for essential tremor. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2005; 64: 2008-20
51. Eisenberg E, Shifrin A, Krivoy N. Lamotrigine for neuropathic pain. Expert Rev Neurother 2005; 5: 729-35
52. Lampl C, Katsarava Z, Diener HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76: 1730-2
53. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006; (4): CD005962
54. Nierneberg IA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatr 2006; 163: 210-6
55. Ondo WG, Jimenez JE, Vuong KD, et al. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004; 27: 274-7
56. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004; 19: 1215-21
57. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005; 64: 1078-80
58. Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. Neurology 2006; 253: 762-6
59. Drake ME, Greathouse NI, Armentbright AD, et al. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia 2001; 21: 373
60. Krusz JC. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia 2001; 21: 373
61. Magenta P, Arghetti S, Di Palma F, et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol Sci 2005; 26: 218-26
62. Raja M, Azzoni A. Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. Int J Neuropsychopharmacol 2003; 6: 409-14
63. MacCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blind, placebo-controlled, crossover study. Anesth Analg 1999; 89: 985-8
64. Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000; 157: 463-5
65. Applebaum J, Levine J, Belmaker RH. Intravenous fosphenytoin in acute mania. J Clin Psychiatry 2003; 64: 408-9
66. Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005; 66: 1401-8
67. Van Ameringen M, Mancini C, Pipe B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65: 1674-8
68. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005; 45: S48-56
69. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002; 59: 132-4
70. Sechi G, Agnetti V, Sulas FM, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1023-7
71. McIntyre RS, Riccardelli R, Binder C, et al. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005; 50: 415-22
72. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005; 28: 277-9
73. Silberstein SD, Walter N, Schmitt J, et al. Topiramate in migraine prevention. Arch Neurol 2004; 61: 490-5
74. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-5
75. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9: 199-216
76. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97: 33-8
77. Winterer G, Hermann WM. Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry 2000; 33: 182-8
78. Keck PE, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54: 305-30
79. Hirschfeld RMA, Baker JD, Wozniak P, et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry 2003; 64: 841-6
80. Swann AC. Valproic acid: clinical efficacy and use in psychiatric disorders. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 828-36
81. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005; 11: 101-3
82. Sabra AF, Hallett M. Action tremor with altering activity in antagonist muscles. Neurology 1984; 34: 151-6
83. Yoshida S, Okada M, Zhu G, et al. Effects of zonisamide on neurotransmitter exocytosis asociated with ryanodine receptors. Epilepsy Res 2005; 67: 153-62
84. Lynch B, Lamberg N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004; 101: 9861-6
85. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat conference (Eilat VII). Epilepsy Res 2002; 51: 31-71
86. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanisms of action of pregabalin: the calcium channel α2-δ (alpha-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73: 137-50
87. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305
88. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627-35
89. Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002; 5: 767-74
90. Shannon HE, Eberle EL, Peters SC. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacol 2005; 48: 1012-20
91. Brill J, Lee M, Zhao S, et al. Chronic valproic acid treatment triggers increased neuropeptide Y expression and signalling in rat nucleus reticularis thalami. J Neurosci 2006; 26: 6813-22
92. Winkler I, Blotnik S, Shimshoni J, et al. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br J Pharmacol 2005; 146: 198-208
93. Winkler I, Sobol E, Yagen B, et al. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacol 2005; 49: 1110-20
94. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006; 15: 637-47
95. Corbo J. The role of anticonvulsants in preventive migraine therapy. Curr Pain Headache 2003; 7: 63-6
96. Erdemolu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. Acta Neurol Scand 2000; 102: 354-8
97. Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology 2004; 62: S2-8
98. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3-14
99. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27: 19-22S
100. Preece NE, Jackson GD, Houseman JA, et al. Nuclear magnetic resonance detection of increased GABA in vigabatrin-treated rats in vivo. Epilepsia 1994; 35: 431-6
101. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs 2001; 15: 339-50
102. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 217-30
103. Sills GJ, Patsalos PN, Butler E, et al. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196-200
104. Krauss GL, Johnson MA, Sheth S, et al. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurosurg Psychiatry 2003; 74: 339-43
105. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37: 103-10
106. Johannessen CU, Johannessen SI. An update on valproate: clinical implications of recent studies for its mechanisms of action (SIIC 2004) [online]. Available from URL: http://www.siicsalud.com/dato/dat038/04707003.htm [Accessed 2007 Sep 17]
107. Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Current Opin Pharmacol 2006; 6: 18-23
108. Bennett S, Gronier B. Modulation of striatal dopamine release in vitro by agonists of the glycine B site of NMDA receptors: interaction with antipsychotics. Eur J Pharmacol 2005; 527: 52-9
109. Hosak L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002; 17: 371-8
110. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-78
111. Anmann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 2005; 46 Suppl. 4: 26-30
112. Greene JG. Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J Physiol 2006; 575: 411-6
113. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5-49
114. Rogawski M. Astrocytes get in the act in epilepsy. Nat Med 2005; 11: 919-20
115. Guo-Feng T, Hooman A, Takano T, et al. An astrocytic basis of epilepsy. Nat Med 2005; 11: 973-81
116. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003; 66: 179-89
117. Cordeiro ML, Gundersen CB, Umbach JA. Convergent effects of lithium and valproate on the expression of proteins associated with large dense core vesicles in NGF-differentiated PC12 Cells. Neuropsychopharmacol 2004; 29: 39-44
118. Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003; 37: 17-24
119. Arban R, Maraia G, Brackenborough K, et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 2005; 158: 123-32
120. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23: 484-95
121. Muzina DJ, Elhaj O, Gajwani P, et al. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand 2005; 111: 21-8
122. Selai C, Bannister D, Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 2005; 46 Suppl. 4: 50-7
123. Berudsky Y. Phenytoin: an anti-bipolar anticonvulsant? Int J Neuropsychopharmacol 2006; 9: 627-8
124. Gajwani P, Forsthoff A, Muzina D, et al. Antiepileptic drugs in mood-disordered patients. Epilepsia 2005; 46 Suppl. 4: 38-44
125. Silberstein SD. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001; 41: S11-7
126. Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005; 17: 20-8
127. Ettinger AB, Reed ML, Goldberg JL, et al. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005; 65: 535-40
128. Schmitz B. Depression and mania in patients with epilepsy. Epilepsia 2005; 46 Suppl. 4: 45-9
129. Kanner AM. Depression in epilepsy: a neurobiological perspective. Epilepsy Curr 2005; 5: 21-7
130. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav 2007; 10: 148-54
131. Jobe PC. Shared mechanisms of antidepressant and antiepileptic treatments: drugs and devices. Clin EEG Neurosci 2004; 35: 25-37
132. Jobe PC. Affective disorder and epilepsy comorbidity: implications for development of treatments, preventions and diagnostic approaches. Clin EEG Neurosci 2004; 35: 53-68
133. Ottman R, Lipton RB. Comorbidity of migraine and epilepsy. Neurology 1994; 44: 2105-10
134. Bigal ME, Lipton RB, Cohen J, et al. Epilepsy and migraine. Epilepsy Behav 2003; 4: S13-24
135. Sechi G, Cocco GA, D'Onofrio M, et al. Disfluent speech in patients with partial epilepsy: beneficial effect of levetiracetam. Epilepsy Behav 2006; 9: 521-3
136. Applebaum J, Gayduk J, Agam G, et al. Valnoctamide as a valproate substitute with low teragenic potential: double-blind controlled clinical trial. Bipolar Disord 2005; 7: 27-117
137. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003; 37: 5-16
138. Yeow WS, Ziauddin MF, Maxhimer JB, et al. Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer 2006; 22: 1436-45
139. Eyal S, Yagen B, Shimshoni J, et al. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active constitutional isomers and derivatives. Biochem Pharmacol 2005; 69: 1501-8
140. Eyal S, Lamb J, Smith-Yockman M, et al. The antiepileptic and chemotherapeutic agent valproic acid induces P-glycoprotein in human tumor cell lines and in rat liver. Br J Pharmacol 2006; 149: 250-60
141. Peixoto MF, Abilio VC, Silva RH, et al. Effects of valproic acid on an animal model of tardive dyskinesia. Behav Brain Res 2003; 142: 229-33
142. Myrick H, Malcolm R, Anton R. The use of antiepileptics in the treatment of addictive disorders. Prim Psychiatry 2003; 10: 59-63
143. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-85
144. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005; 18: 265-70
145. Brodie JD, Figuerosa E, Laska EM, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55: 122-5
146. Brown ES, Perantie DC, Dhanani N, et al. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord 2006; 93: 219-22
147. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial (Pt 1): improvement in binge and purge measures. J Clin Psych 2003; 64: 1335-41
148. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int Eat Disord 2005; 38: 295-300
149. Lomia M, Tchelidze T, Pruidze M. Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. Respir Med 2006; 100: 1988-96
150. Costa C, Martella G, Picconi B, et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006; 37: 1319-26
151. Wallis RA, Panizzon KL, Niquet J, et al. Neuroprotective effects of the anticonvulsant, fluorofelbamate [abstract]. Epilepsia 2000; 41: 162-3
152. Dou H, Birusingh K, Faraci J, et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003; 23: 9162-70
153. De Paulis T. ONO-2506. Curr Opin Invest Drug 2003; 4: 863-7